{"id":3720,"date":"2019-02-07T15:56:53","date_gmt":"2019-02-07T06:56:53","guid":{"rendered":"https:\/\/www.peptide.co.jp\/en\/?p=3720"},"modified":"2024-11-20T16:38:54","modified_gmt":"2024-11-20T07:38:54","slug":"3919","status":"publish","type":"post","link":"https:\/\/www.peptide.co.jp\/en\/new-product\/3919.html","title":{"rendered":"Deoxyfructosyl Peptides\/Amino Acids"},"content":{"rendered":"

Reducing sugars such as glucose are known to glycosylate proteins by non-enzymatic reaction with amino groups of proteins in vivo<\/i>. The series of reactions is known as the Maillard reaction starting from Amadori rearrangement, and the modified compounds are called Amadori compounds and\/or Maillard compounds. After oxidation and dehydration reaction, it leads to AGEs (Advanced Glycation End Products). AGEs typified by Pentosidine<\/a> have been reported to affect age-related diseases.
\n\u3000
\n\"Figure<\/p>\n

Figure 1. Amadori rearrangement reaction of D-glucose with N<\/i>-terminal Val residue of hemoglobin in vivo<\/i>.<\/div>\n

\u3000
\n\u3000
\nGlycosylated hemoglobin A1c (HbA1c) is an Amadori compound in which blood glucose is bound to the N<\/i>-terminal Val residue of hemoglobin \u03b2 chain. HbA1c is used as a diagnostic marker for diabetes, and its amount can be measured by the enzymatic method as shown in Figure 2.
\n\u3000
\n\"Figure<\/p>\n

Figure 2. Measurement of HbA1c by enzymatic method.<\/div>\n

\u3000
\n\u3000
\nWe have released several deoxyfructosyl products in small amount package size.
\n\u3000
\n\u3000<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
Code<\/td>\nProduct<\/td>\nQuantity<\/td>\n<\/tr>\n
24011-v<\/a><\/td>\n1-Deoxyfructosyl-Gly<\/td>\n1 mg vial<\/td>\n<\/tr>\n
24012-v<\/a><\/td>\nLys(1-Deoxyfructosyl)<\/td>\n1 mg vial<\/td>\n<\/tr>\n
24013-v<\/a><\/td>\n1-Deoxyfructosyl-Val [Fru-Val]<\/td>\n1 mg vial<\/td>\n<\/tr>\n
24014-v<\/a><\/td>\n1-Deoxyfructosyl-Val-His [Fru-Val-His]<\/td>\n1 mg vial<\/td>\n<\/tr>\n
24015-v<\/a><\/td>\n1-Deoxyfructosyl-Val-His-Leu-Thr-Pro-Glu<\/td>\n1 mg vial<\/td>\n<\/tr>\n
3413-v<\/a><\/td>\nVal-His-Leu-Thr-Pro-Glu<\/td>\n0.5 mg vial<\/td>\n<\/tr>\n
3417-s<\/a><\/td>\nLys(1-Deoxyfructosyl[13<\/sup>C6<\/sub>])<\/td>\n0.1 mg vial<\/td>\n<\/tr>\n
3256-v<\/a><\/td>\nCarboxymethyllysine<\/td>\n1 mg vial<\/td>\n<\/tr>\n
24019-v<\/a><\/td>\n3-Deoxyglucosone<\/td>\n1 mg vial<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u3000
\n\u3000
\nBulk supply as well as custom synthesis of different glycosylation reaction products such as 3-Deoxyglucosone (3-DG) \/ Carboxymethyl Lysine (CML), and AGEs are available on request. Please feel free to contact us.<\/a><\/p>\n

\n","protected":false},"excerpt":{"rendered":"

Reducing sugars such as glucose are known to glycosylate proteins by non-enzymatic reaction with amino groups of proteins in vivo. The series of reactions is known as the Maillard reaction starting from Amadori rearrangement, and the modified compounds are called Amadori compounds and\/or Maillard compounds. After oxidation and dehydration reaction, it leads to AGEs (Advanced Glycation End Products). AGEs typified by Pentosidine have been reported to affect age-related diseases. \u3000 Figure 1. Amadori rearrangement reaction of D-glucose with N-terminal Val residue of hemoglobin in vivo. \u3000 \u3000 Glycosylated hemoglobin A1c (HbA1c) is an Amadori compound in which blood glucose is bound to the N-terminal Val residue of hemoglobin \u03b2 chain. […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-3720","post","type-post","status-publish","format-standard","hentry","category-new-product"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/posts\/3720","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/comments?post=3720"}],"version-history":[{"count":16,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/posts\/3720\/revisions"}],"predecessor-version":[{"id":5649,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/posts\/3720\/revisions\/5649"}],"wp:attachment":[{"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/media?parent=3720"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/categories?post=3720"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/tags?post=3720"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}